Related Experiment Video
Updated: May 5, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
Published on: October 12, 2017
Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease
Christian Besler1, Kathrin Heinrich, Lucia Rohrer
1Cardiology, Cardiovascular Center, University Hospital Zurich, Zurich, Switzerland.
High-density lipoprotein (HDL) from coronary artery disease (CAD) patients loses its protective endothelial effects. This occurs because HDL activates lectin-like oxidized LDL receptor 1 (LOX-1), inhibiting nitric oxide production crucial for vascular health.
Area of Science:
- Cardiovascular Biology
- Endothelial Function
- Lipid Metabolism
Background:
- High-density lipoprotein (HDL) is investigated for coronary artery disease (CAD) treatment due to its presumed atheroprotective endothelial effects.
- However, HDL's impact on endothelial function in CAD patients, specifically its effects on endothelial nitric oxide synthase (eNOS) pathways, remains unclear.
Purpose of the Study:
- To investigate the endothelial effects of HDL from patients with CAD.
- To elucidate the mechanisms by which CAD-associated HDL may impair endothelial function and nitric oxide (NO) production.
Main Methods:
- Comparison of HDL from healthy subjects versus HDL from CAD patients (HDLCAD) regarding endothelial anti-inflammatory and repair effects.
- Assessment of HDLCAD's impact on endothelial NO production, eNOS activation, and related signaling pathways.
- Investigation of the role of lectin-like oxidized LDL receptor 1 (LOX-1) and protein kinase C beta-II (PKCβII) activation.
- Analysis of HDL-associated paraoxonase 1 (PON1) activity and malondialdehyde levels.
Main Results:
- HDL from CAD patients (HDLCAD) failed to provide anti-inflammatory effects or stimulate endothelial repair, unlike HDL from healthy individuals.
- HDLCAD activated endothelial LOX-1, leading to PKCβII activation, which inhibited eNOS-activating pathways and NO production.
- Reduced HDL-associated PON1 activity was identified as a key factor contributing to these detrimental endothelial effects of HDLCAD, linked to increased malondialdehyde formation.
Conclusions:
- In CAD patients, HDL acquires properties that activate endothelial LOX-1 and PKCβII due to diminished PON1 activity.
- This activation pathway inhibits eNOS signaling, resulting in the loss of HDL's beneficial anti-inflammatory and endothelial repair-stimulating effects.
- These findings reveal a novel mechanism for endothelial dysfunction in CAD mediated by altered HDL properties.
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Coronary Artery Disease I: Introduction
Coronary Artery Disease II: Pathophysiology
Atherosclerosis I: Introduction
Atherosclerosis III: Management

